Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms, Male × abemaciclib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 30 Neoplasm Metastasis 7 Brain Neoplasms 6 Prostatic Neoplasms 4 Neoplasms 4 Glioma 4 Glioblastoma 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Unilateral Breast Neoplasms 2 Triple Negative Breast Neoplasms 2 Sarcoma, Ewing 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Meningioma 2 Colorectal Neoplasms 2 Breast Diseases 2 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Kaposi 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms, Squamous Cell 1

Interventions

exemestane 2 Tamoxifen 2 Leuprolide 2 Letrozole 2 Immunotherapy 2 Goserelin 2 Anastrozole 2 ribociclib 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abemaciclib 1 Neoadjuvant Therapy 1 Immunoenzyme Techniques 1 Everolimus 1 Blood Specimen Collection 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05501704 2026-01-07

ETHAN - ET for Male BC

Dana-Farber Cancer Institute

Phase 2 Recruiting

Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡